Tocotrienols group (n = 30) | Changes at completion of the study | |||
---|---|---|---|---|
Baseline | Negative | Mild | Moderate | Severe |
Mild (n = 22) | 13/22 | 9/22 | 0/22 | 0/22 |
73.3% | 59.1% | 40.9% | 0.0% | 0.0% |
Moderate (n = 6) | 2/6 | 4/6 | 0/6 | 0/6 |
20.0% | 33.3% | 66.7% | 0.0% | 0.0% |
Severe (n = 2) | 0/2 | 1/2 | 0/2 | 1/2 |
6.7% | 0.0% | 50.0% | 0.0% | 50.0% |
  TOTAL | 15/30 | 14/30 | 0/30 | 1/30 |
 | 50.0% | 46.7% | 0.0% | 3.3% |
Placebo group (n = 34) | Changes at completion of the study | |||
Baseline | Negative | Mild | Moderate | Severe |
Mild (n = 27) | 8/27 | 17/27 | 2/27 | 0/27 |
79.4% | 29.6% | 63.0 | 7.4% | 0.0% |
Moderate (n = 6) | 0/6 | 5/6 | 1/6 | 0/6 |
17.6% | 0.0% | 83.3% | 16.7% | 0.0% |
Severe (n = 1) | 0/1 | 0/1 | 1/1 | 0/1 |
2.9% | 0.0% | 0.0% | 100.0% | 0.0% |
  TOTAL | 8/34 | 22/34 | 4/34 | 0/34 |
 | 23.5% | 64.7% | 11.8% | 0.0% |
Tocotrienols vs Placebo | Chi Sq = 4.851 | P = 0.014 |  |  |